IOncology

Vebreltinib, a highly potent and selective c-MET (mesenchymal-epithelial transition) inhibitor, offers a promising treatment option for patients with MET exon 14 skipping mutation (METex14) in non-small cell lung cancer (NSCLC). Can it provide a safe and effective therapy for these patients?

A large population-based cohort study led by Dr. Mollie E. Barnard from the Huntsman Cancer Institute at the University of Utah has found that women with endometriosis have an overall higher risk of ovarian cancer, with the risk being significantly elevated in those with severe types of endometriosis. This study, published in the journal of the American Medical Association [1], suggests that these women may benefit from counseling on ovarian cancer risk and prevention, as well as potential ovarian cancer screening.

With an international perspective and a focus on leading-edge advancements, the Overseas Experts China Tour project welcomed a prominent figure in the field of lung cancer from August 5th to 10th, 2024—Dr. Jürgen Wolf, Director of the Centre for Integrated Oncology (CIO) at University Hospital of Cologne, Professor of Interdisciplinary Translational Oncology at the University of Cologne, and Head of the CIO Lung Cancer Program. During his five-day academic exchange tour in China, Professor Wolf visited Chengdu, Hangzhou, Changsha, and Qingdao, attracting lung cancer experts from across the country for discussions and exchanges. Throughout these academic activities, Professor Wolf not only shared the experiences of lung cancer diagnosis and treatment in Germany but also engaged in vigorous academic discussions with Chinese experts on the latest advancements and contentious topics in lung cancer treatment, sparking many brilliant ideas.

The International Association for the Study of Lung Cancer (IASLC) is set to host the 2024 World Conference on Lung Cancer (WCLC) from September 7-10 in San Diego, California. Dr. Eric Singhi, a thoracic oncologist at MD Anderson Cancer Center, recently shared with international media the key studies he is most eager to follow at the 2024 WCLC.

In recent years, bilateral mastectomy, as a surgical approach to prevent contralateral breast cancer, has gained a certain degree of attention and application. However, there is still controversy regarding the actual effectiveness of bilateral mastectomy in preventing breast cancer mortality. Recently, Dr. Steven Narod from the Dalla Lana School of Public Health published a research paper titled "Bilateral Mastectomy and Breast Cancer Mortality" in JAMA Oncology. "Oncology Frontier" specially invited Dr. Steven Narod to share his latest research findings, hoping to provide more thoughts and guidance for the prevention, diagnosis, and treatment of breast cancer.

The necessity of adding chemotherapy to postoperative adjuvant treatment and in Stage IV non-small cell lung cancer (NSCLC) remains a topic of debate. In this article, Dr. Mark G. Kris from Memorial Sloan Kettering Cancer Center analyzes the value of chemotherapy in the adjuvant treatment of early-stage NSCLC with EGFR and ALK mutations, as well as in the treatment of advanced lung cancer.

The successes of immunotherapy and targeted therapy in metastatic non-small cell lung cancer (NSCLC) have raised hopes for implementing these therapies in earlier stages of the disease. Recent trial results indicate that neoadjuvant, adjuvant, and perioperative immunotherapy may improve the cure rates of early-stage NSCLC. While early diagnosis of patients could make immunotherapy a significant option for early-stage NSCLC, identifying reliable biomarkers remains a challenge.

In 2022, Dr. Chunxue Bai from Fudan University Shanghai Cancer Center, introduced the concept of "Metaverse Medicine," aiming to leverage metaverse technology to revolutionize disease prevention and treatment. At the 2024 International Lung Cancer Academic Conference, Professor Bai presented a report titled "Lung Cancer Screening and Management in the Metaverse Era." This article provides a summary of the main points of his report.

PostMONARCH is the first randomized, placebo-controlled phase III study of its kind. At the 2024 ASCO conference, Dr. Kevin Kalinsky from the Winship Cancer Institute of Emory University presented the primary outcomes of the PostMONARCH study, revealing that continued treatment with abemaciclib (Abemaciclib) + fulvestrant benefits patients even after progression on CDK4/6 inhibitor therapy. This article provides a summary of the study's progress for our readers.